Obesity, diabetes, metabolic diseases: how to improve prevention and support public health

New tests for endocrine disruptors will help identify these chemicals

The Project

Combining computational, experimental and epidemiological studies to improve public health

Innovative computational approaches support a better interpretation of populational and experimental studies

The Project

11 partners involved and numerous stakeholders all around Europe

An European Commission co-funded project involving 8 EU organizations, with a budget of over 6.7 million €

The Consortium

EURION: Cooperation from all projects co-funded on EDs, at European level

The EURION cluster strength to optimize synergies between the 8 EU co-funded projects

Cluster

PRESENTATION

Context

Exposure to chemical substances that can produce endocrine disrupting effects represents one of the most critical public health threats nowadays. In line with the regulatory framework implemented within the European Union to reduce the levels of endocrine disruptors (EDs) for consumers, new and effective methods for ED testing are needed.

Objectives

The OBERON project will build an integrated approach for testing and assessment (IATA) to detect endocrine disruptors-related metabolic disorders by developing, improving and validating a battery of test systems.



Description
OBERON will combine:
1

Experimental methods: in vitro e.g. on 2D and 3D human-derived cells and tissues, and in vivo i.e. in zebrafish

2

High throughput omics technologies

3

Epidemiology and human biomonitoring studies

4

Advanced computational models: in silico (QSAR, PBPK) and systems biology

OBERON will allow:
1

To build a mechanistic understanding of toxicity in order to detect ED

2

To help identifying effective and alternative tests, relevant for human health and in line with regulatory needs

3

To contribute to the development of novel Adverse Outcome Pathways (AOPs) and AOP networks

OBERON IN NUMBERS

0

Partners

0

European countries

0

years project

0

Workpackages

0

Budget (M€)

0

SME


OBERON is a collaborative project funded by the EU Framework Programme for Research and Innovation Action (RIA), Horizon 2020, under Grant Agreement no 825712. With a budget of over 5.9 million €, OBERON started on 1st January 2019 and will last for a duration of 5 years.


THE PROJECT

Exposure to chemical substances that can produce endocrine disrupting effects represents one of the most critical public health threats nowadays. In line with the regulatory framework implemented within the European Union to reduce the levels of endocrine disruptors (EDs) for consumers, new and effective methods for ED testing are needed. The OBERON project will build an integrated testing strategy (ITS) to detect EDs-related metabolic disorders by developing, improving and validating a battery of test systems. It will be based on the concept of an integrated approach for testing and assessment (IATA).

EXPECTED RESULTS

The direct impacts will be:

  • To set up and make available an innovative battery of new, easy to use, effective and validated test systems, combining different experimental and computational strategies, to be used for regulatory aspects regarding ED assessment in relation to metabolic disorders.
  • To improve knowledge on EDs based on data generated by OBERON in cell biology, zebrafish, omics technologies and systems biology. Novel mechanistic knowledge will be established, allowing development of novel Adverse Outcome Pathways (AOPs), as well as integration of information in existing AOPs, and identification of novel biomarkers to improve risk assessment frameworks for human health effects.

CONSORTIUM

Partners from 5 EU countries are involved in the project.

The project is coordinated by INSERM :

Europe
France
  • ANSES - agence nationale de la sécurité sanitaire de l'alimentation, de l'environnement et du travail
  • INERIS - institut national de l'environnement et des risques
  • INSERM - institut national de la santé et de la recherche médicale
  • IT - INSERM Transfert
Italy
  • IRFMN - istituto di ricerche farmacologiche mario negri
Czech Republic
  • IBP - biofyzikalni ustav akademie ved ceske republiky
  • MU - masarykova univerzita
Greece
  • AUTH - aristotelio panepistimio thessalonikis - eidikos logariasmos kondilion erevnas
  • EnvE.X - SME, Thessaloniki
Spain
  • ISGLOBAL - fundacion privada instituto de salud global barcelona
  • UMH - universidad miguel hernandez de elche

EURION: A CLUSTER FOCUS ON ENDOCRINE DISRUPTORS

In order to optimize synergies and avoid overlaps between the projects selected for funding from the call SC1-BHC-27-2018 ‘New testing and screening methods to identify endocrine disrupting chemicals’, the projects will form a cluster. It is named EURION for “European Cluster to Improve Identification of Endocrine Disruptors”. This cluster was launched on January 1st 2019.

LATEST NEWS

The OBERON project has started on 1st January 2019

OBERON Kick-Off Meeting took place on the 8st of February 2019 in Brussels, Belgium. This meeting gathered all 11 partners from 6 countries for presenting the planned work program.

Continue Reading
Joint Launch Event of Projects

Joint Launch Event of Projects from the Call ‘New Testing and Screening Methods to Identify Endocrine Disrupting Chemicals’ - 31 January, 2019, Brussels

Continue Reading
Towards a Better System for Identifying Endocrine Disruptors

Article from the INSERM website, introducing the project

Continue Reading

MEETINGS

OBERON Consortium Meetings

2020

  • 06 & 07 February 2020: OBERON Annual meeting

Cluster Meetings

2019

  • October 2019: Webinar with the International Advisory Panel

2020

  • 04 & 05 February 2020: Annual Cluster meeting

Conferences

Forthcoming

© OBERON 2019, Website Created by FMOSys